Filing Flows › Comparisons › AZN vs LLY
AstraZeneca vs ELI Lilly: AZN and LLY compared
AstraZeneca is the larger company: $30.7B of revenue in its latest quarter (Q2 2026) against $24.4B for ELI Lilly (Q3 2026). ELI Lilly is growing faster (+39% against +9% a year earlier). ELI Lilly is more profitable, with an operating margin of 34.5% against 24.2%.
Where the money goes: AZN and LLY
AstraZeneca (AZN) · Q2 2026
AstraZeneca, Q2 2026: revenue $30.7B (+9% year over year), operating margin 24.2%, net earnings $5.6B. The chart follows the revenue to costs, profit and cash.
ELI Lilly (LLY) · Q3 2026
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
| AstraZeneca (AZN) | ELI Lilly (LLY) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $30.7B | $24.4B |
| Revenue growth, Y/Y | +9% | +39% |
| Gross margin | 83.0% | — |
| Operating margin | 24.2% | 34.5% |
| Net earnings | $5.6B | $6.5B |
| Net margin | 18.2% | 26.4% |
| Operating cash flow | — | $11.4B |
| Free cash flow | — | $8.2B |
| Market value | — | $1.22T |
| P/E | — | 44.3× |
| Analysts’ mean target | — | $1453.40 |
Where the revenue comes from
AstraZeneca
- Oncology: $14.1B (46%)
- BioPharmaceuticals: $11.2B (36%)
- Rare Disease: $4.9B (16%)
- Other Medicines: $486M (2%)
ELI Lilly
- Net product revenue: $22.7B (93%)
- Other oncology: $1.1B (4%)
- Other immunology: $579M (2%)
Questions
Which is bigger, AstraZeneca or ELI Lilly?
AstraZeneca is the larger company: $30.7B of revenue in its latest quarter (Q2 2026) against $24.4B for ELI Lilly (Q3 2026).
Is AstraZeneca or ELI Lilly growing faster?
ELI Lilly is growing faster (+39% against +9% a year earlier).
Which is more profitable, AstraZeneca or ELI Lilly?
ELI Lilly is more profitable, with an operating margin of 34.5% against 24.2%.
More: AstraZeneca earnings · how AstraZeneca makes money · ELI Lilly earnings · how ELI Lilly makes money
From the companies' latest 10-Q, 10-K or earnings release (6-K filed Jul 27, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.